Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: Experience in a drug development programme for maraviroc

Antiviral Therapy

Volumn 12, Issue 2, 2007, Pages 233-245

  Wheeler, Jeremy ^a   McHale, Mary ^a   Jackson, Vicky ^a   Penny, Michelle ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; MARAVIROC; RIBAVIRIN;

ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; INFECTION SENSITIVITY; META ANALYSIS; MONOTHERAPY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PUBLICATION; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SCIENTIFIC LITERATURE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; ARTHRITIS, RHEUMATOID; CYCLOHEXANES; DRUG DESIGN; FEMALE; GENOTYPE; HEPATITIS C; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; MALE; MULTIPLE SCLEROSIS; MUTATION; PHARMACOGENETICS; RECEPTORS, CCR5; RISK ASSESSMENT; RISK FACTORS; TRIAZOLES;

EID: 34147102357     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Drews J. Drug discovery: a historical perspective. Science 2000; 287:1960-1964.
2. Penny MA, McHale D. Pharmacogenomics and the drug discovery pipeline: when should it be implemented? Am J Pharmacogenomics 2005; 5:53-62.
3. Fatkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005; 11: 1170-1172.
4. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367-377.
5. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722-725.
6. Eugen-Olsen J, Eversen AK, Garred P, et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 1997; 11:305-310.
7. Feinberg J. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). New CCR5 antagonist shows antiretroviral effect. AIDS Clin Care 2003; 15:94-95.
8. van Rij RP, Portegies P, Hallaby T, et al. Reduced prevalence of the CCR5 delta32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex. J Infect Dis 1999; 180:854-857.
9. Prahalad S. Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis. Genes Immun 2006; 7:264-268.
10. Woitas RP, Ahlenstiel G, Iwan A, et al. Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in heparitis C. Gastroenterology 2002; 122:1721-1728.
11. Wasmuth HE, Werth A, Mueller T, et al. CC chemokine receptor 5 delta32 polymorphism in two independent cohorts of hepatitis C virus infected patients without hemophilia. J Mol Med 2004; 82:64-69.
12. Konishi I, Horiike N, Hiasa Y, Michitaka K, Onji M. CCR5 promoter polymorphism influences the interferon response of patients with chronic hepatitis C in Japan. Intervirology 2004; 47:114-120.
13. Kantor R, Barzilai A, Varon D, Martinowitz U, Gershoni JM. Prevalence of a CCR5 gene 32-bp deletion in an Israeli cohort of HIV-1-infected and uninfected hemophilia patients. J Hum Virol 1998; 1:299-301.
14. Gade-Andavolu R, Comings DE, MacMurray J, et al. Association of CCR5 Delta32 deletion with early death in multiple sclerosis. Genet Med 2004; 6:126-131.
15. Barcellos LF, Schifo AM, Rimmler JB, et al. CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Immunogenetics 2000; 51:281-288.
16. Hellier S, Frodsham AJ, Hennig BJ, et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 2003; 38:1468-1476.
17. Mascheretti S, Hinrichsen H, Ross S, et al. Genetic variants in the CCR gene cluster and spontaneous viral elimination in hepatitis C-infected patients. Clin Exp Immunol 2004; 136:328-333.
18. Promrat K, McDermott DH, Gonzalez CM, et al. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology 2003; 124:352-630.
19. Klein RS. Discussion on frequency of the HIV-protective CC chemokine receptor 5-Delta 32/Delta 32 genotype is increased in hepatitis C.[comment]. Gastroenterology 2003; 124:1558; author reply 1560-1561.
20. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2:1240-1243.
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560.
22. Egger M, Davey-Smith SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634.
23. Glas J, Torok HP, Simperl C, et al. The Delta 32 mutation of the chemokine-receptor 5 gene neither is correlated with chronic hepatitis C nor does it predict response to therapy with interferon-α and ribavirin. Clin Immunol 2003; 108:46-50.
24. Mangia A, Santoro R, D'agruma L, Andriulli A. HCV chronic infection and CCR5-Delta32/Delta32. Gastroenterology 2003; 124:868-870.
25. Poljak M, Tomazic J, Seme K, Maticic M, Vidmar L. Prevalence of mutant CCR5 allele in Slovenian HIV-1-infected and non-infected individuals. Acta Virol 1998; 42:23-26.
26. Ruiz-Ferrer M, Barroso N, Antinolo G. & Aguilar-Reina J. Analysis of CCR5-Delta 32 and CCR2-V64I polymorphisms in a cohort of Spanish HCV patients using real-time polymerase chain reaction and fluorescence resonance energy transfer technologies. J Viral Hepat 2004; 11:319-323.
27. Thoelen I, Verbeeck J, Wollants Eet al. Frequency of the CCR5-Delta32 mutant allele is not increased in Belgian hepatitis C virus-infected patients. Viral Immunol 2005; 18:232-235.
28. Tommasi AM, Fabris P, Carderi I. et al. Lack of higher frequency of the chemokine receptor 5-Delta32 /Delta32 genotype in hepatitis C. J Clin Gastroenterol 2006; 40:440-443.
29. Goyal A, Suneetha PV, Kumar GT, Shukla DK, Arora N, Sarin SK. CCR5(Delta)32 mutation does not influence the susceptibility to HCV infection, severity of liver disease and response to therapy in patients with chronic hepatitis C. World J Gastroenterol 2006; 12:4721-4726.
30. Ahlenstiel G, Berg T, Woitas RP, et al. Effects of the CCR5-delta32 mutation on antiviral treatment in chronic hepatitis C. J Hepatol 2003; 39:245-252.
31. Dorak MT, Folayan GO, Niwas S, et al. C-C-chemokine receptor 2 and C-C-chemokine receptor 5 genotypes in patients treated for chronic hepatitis C virus infection. Immunol Res 2002; 26:167-175.
32. Bennetts BH, Teutsch SM, Buhler MM, Heard RN, Stewart GJ. The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum Immunol 1997; 58:52-59.
33. Favorova OO, Andreewski TV, Boiko AN, et al. The chemokine receptor CCR5 deletion mutation is associated with MS in HLA-DR4-positive Russians. Neurology 2002; 59:1652-1655.
34. Luomala M, Lehtimaki T, Huhtala H, et al. Promoter polymorphism of IL-10 and severity of multiple sclerosis. Acta Neurol Scand 2003; 108:396-400.
35. Pulkkinen K, Luomala M, Kuusisto H, et al. Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis. Acta Neurol Scand 2004; 109:342-347.
36. Schreiber K, Otura AB, Ryder LP, et al. Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E). Mult Scler 2002; 8:295-298.
37. Sellebjerg F, Madsen HO, Jensen CV, Jensen J, Garred P. CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol 2000; 102:98-106.
38. Silversides JA, Heggarty SV, McDonnell GV, Hawkins SA, Graham CA Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course. Mult Scler 2004 10:149-152.
39. Cooke SP, Forrest G, Venables PJ, Hajeer A. The delta32 deletion of CCR5 receptor in rheumatoid arthritis. Arthritis Rheum 1998; 41:1135-1136.
40. Garred P, Madsen HO, Petersen J, et al. CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol 1998; 25:1462-1465.
41. Gomez-Reino JJ, Pablos JL, Carreira PE, et al. Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. Arthritis Rheum 1999; 42:989-992.
42. Pokorny V, McQueen F, Yeoman S, et al. Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis. Ann Rheum Dis 2005; 64:487-490.
43. Zapico I, Coto E, Rodriguez A, Alvarez C, Torre JC, Alvarez V. CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes Immun 2000; 1:288-289.
44. Zuniga JA, Villarreal-Garza C, Flores E, et al. Biological relevance of the polymorphism in the CCR5 gene in refractory and non-refractory rheumatoid arthritis in Mexicans. Clin Exp Rheum 2003; 21: 351-354.
45. Goulding C, McManus R, Murphy A, et al. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut 2005; 54:1157-1161.
46. Amin J, Kaye M, Skidmore S, Pillay D, Cooper DA, Dore GJ. HIV and hepatitis C coinfection within the CAESAR study. HIV Med 2004; 5:174-179.
47. Balashov KE, Rottman JB, Weiner HL, Hancock WW. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Nat Acad Sci USA 1999; 96:6873-6878.
48. Mahad DJ, Lawry J, Howell SJ, Woodroofe MN. Longitudinal study of chemokine receptor expression on peripheral lymphocytes in multiple sclerosis: CXCR3 upregulation is associated with relapse. Mult Scler 2003; 9:189-198.
49. Sorensen TL, Tani M, Jensen J, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999; 103:807-815.
50. Haase CG, Schmidt S, Faustmann PM. Frequencies of the G-protein beta3 subunit C825T polymorphism and the delta 32 mutation of the chemokine receptor-5 in patients with multiple sclerosis. Neurosci Lett 2002; 330:293-295.
51. Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006; 203:35-40.
52. Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet 2003; 361:865-872.